COMMUNIQUÉS West-GlobeNewswire

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
05/03/2026
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults in more than [...]
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
05/03/2026
WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) [...]
Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA
05/03/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 05, 2026 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
05/03/2026
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug [...]
Calidi Biotherapeutics Announces Proposed Public Offering
05/03/2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
05/03/2026
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Announced encouraging preliminary safety and efficacy [...]
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
05/03/2026
ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
05/03/2026
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America [...]
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
05/03/2026
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “ [...]
Omada Health Reports Fourth Quarter and Full-Year 2025 Results
05/03/2026
Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for Year Achieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year [...]
COSCIENS Provides Strategic Update
05/03/2026
TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“ COSCIENS ” or the “ Company ”) today announced that the Company has made a strategic decision to cease funding [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
05/03/2026
Please see enclosed pdf. Attachment 03052026_trading_in_shares_CHE
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
05/03/2026
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability At the maximally effective dose, there were no cases of [...]
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity
05/03/2026
Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and [...]
Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft Therapeutics
05/03/2026
Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs) Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed from Tufts [...]
Quanta Therapeutics Presents Preclinical Data Establishing that Direct Multi-KRAS Inhibitors Retain Strong Activity Against Resistance Mechanisms Acquired from Treatment with pan-RAS Tri-Complex Inhibitors
05/03/2026
– Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to daraxonrasib in KRAS-mutated colorectal cancer cells – – Data support potential benefit [...]
Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions
05/03/2026
ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI) , a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to announce several [...]
Buck Institute Launches Healthspan Horizons to Make Long-Term Health Measurable and Actionable
05/03/2026
New federated research platform links real-world data with aging science to extend healthy years of life NOVATO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- The Buck Institute for Research on Aging today announced the [...]
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
05/03/2026
Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the [...]

Pages